Knee osteoarthritis clinic marketing: cure and cartilage claims, injections, free seminars and referrals

A knee osteoarthritis clinic speaks to people who wince on the stairs, who stop walking the dog because the knee swells afterwards, who were told they are “not ready” for surgery, and to the family members who drive them to appointments. The clinic may sit inside an orthopedic group, a sports medicine or pain practice, a primary care group, a physical therapy clinic or a stand-alone “knee center”. This guide covers what the federal sources say about osteoarthritis, how to write about nonsurgical care without promising to reverse it or regrow cartilage, how to describe injections in the terms of their FDA status, why stem cell offers for knee pain are a problem, how free seminar meals meet the federal rules on inducements, and where the warning signs belong.

Eight related topics have their own guides and are not repeated here. Surgery programs are covered in our guide to joint replacement marketing, and cell and exosome offers in full in our guide to stem cell clinic advertising. Orthopedic group marketing is covered in our guide to orthopedic practice marketing, injury care in our guide to sports medicine practice marketing, and chronic pain programs in our guide to pain management clinic marketing. Exercise programs are covered in our guide to physical therapy marketing ideas, weight programs in our guide to weight loss clinic marketing, and inflammatory arthritis in our guide to rheumatology practice marketing. Joint pain clinics that also treat gout should read gout clinic marketing.

What NIAMS and MedlinePlus say

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) leads federal research on osteoarthritis, and MedlinePlus from the National Library of Medicine publishes the federal patient pages. The points that shape a knee clinic’s marketing:

• The NIAMS Osteoarthritis page (last reviewed September 2023, about three years old) says osteoarthritis happens when the cartilage and other tissues within the joint break down or change in structure, and that as symptoms worsen over time, activities such as stepping up, getting in and out of a chair or walking across a parking lot become difficult. It names being overweight and a history of injury or surgery to a joint among the risk factors.
• The NIAMS Osteoarthritis: Diagnosis, Treatment, and Steps to Take page (last reviewed September 2023) lists the goals of treatment as reducing pain and other symptoms, improving joint function and stopping the disease from progressing. It describes exercise, weight management, braces fitted by a health care professional, heat and cold, canes and walkers, medicines, injections into the joint and, if other treatments are not helping and joint damage is extensive, surgery. It says a doctor will determine the number of injections a person should receive and their timing, and it names orthopaedic surgeons, physical therapists, dietitians and physiatrists among the professionals who treat the disease.
• The MedlinePlus encyclopedia article Osteoarthritis (review date April 9, 2026) says OA cannot be cured, but OA symptoms can be controlled, and that OA will likely get worse over time, at a pace that varies from person to person. It says staying active and getting exercise can maintain joint and overall movement, and tells people to contact their provider if symptoms are bothersome or get worse.
• The MedlinePlus encyclopedia article Knee pain (review date November 7, 2024) tells people to contact their provider if they cannot bear weight on the knee, have severe pain even when not bearing weight, have a fever, redness or warmth around the knee or marked swelling, or have pain, swelling, numbness, tingling or bluish discoloration in the calf below the sore knee.
• The MedlinePlus Osteoarthritis page (last updated January 8, 2024, older than two years) says that in a healthy joint, cartilage covers the ends of the bones and helps them glide when the joint moves.

The NIAMS pages are about three years old, so before relaying them we checked for anything newer. A search of FDA drug label data through openFDA on October 30, 2026 returned labels updated as recently as September 2026 that name osteoarthritis or osteoarthritis of the knee in their indications; the approved drug labels we found treat the signs and symptoms or the pain of osteoarthritis, and none describes a cure or a regrowth of cartilage. The FDA list of Approved Cellular and Gene Therapy Products (content current as of September 17, 2026) includes one product for the knee, and its FDA product page (content current as of August 26, 2024) gives its indication as the repair of symptomatic full-thickness cartilage defects of the knee in adults, which is a surgical product for a defined defect and not a treatment for osteoarthritis. The MedlinePlus line that OA cannot be cured therefore still stands. Run the same check at each review.

Two points shape the marketing. First, osteoarthritis is a long-term condition that the sources describe controlling, not undoing, so a page that promises a new knee without surgery says more than any source here. Second, a knee clinic sees people over 60 who are weighing surgery, and they deserve the same plain facts about each option, including the option the clinic does not offer.

“Regrow your cartilage” and other claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “knee osteoarthritis cure” and “knee arthritis treatment without surgery” to a person who starts typing “knee arthritis cure”, “can knee osteoarthritis be reversed” and “can bone on bone knee arthritis be reversed” after “can knee arthritis be reversed”, “regrow knee cartilage injection” and “regrow knee cartilage with stem cells” after “regrow knee cartilage”, and “gel injections for knees reviews” and “gel injections for knees cost” after “gel injections for knees”. A clinic page can answer those questions honestly: quote MedlinePlus that OA cannot be cured but symptoms can be controlled, list the treatment goals NIAMS names, and say the plan depends on the person’s knee, health and goals.

Phrases that need rewriting:

• “Reverse your knee arthritis.” MedlinePlus says OA cannot be cured, and our label search found no approved drug that claims to reverse it. Remove it, and describe treatment goals in the NIAMS terms.
• “Regrow cartilage without surgery.” No source here shows that an injection, device or supplement regrows cartilage in knee osteoarthritis. Remove it.
• “Avoid knee replacement forever.” A result promise. NIAMS lists surgery as an option when other treatments are not helping and joint damage is extensive. Remove it, and say the clinic offers nonsurgical care and refers to a surgeon when that is the better fit.
• “Bone on bone? Our gel injections fix it.” A result promise for an injection. Remove it, and describe injections only in the terms of their FDA status and labelled use.
• “Our treatment works for 9 out of 10 patients.” An outcome number with no source. Remove it unless it is quoted from a named, published source with its date and limits.
• “No pills, no surgery, no downtime.” An implied claim that the clinic’s option is free of risk and better than the others. Remove it, and state the risks a clinician lists for the procedure.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. A photo of a grandparent kneeling in the garden next to “say goodbye to knee pain” is a health benefit claim even without a number.

Warning signs and 911 on every page and in every tool

A knee clinic gets calls about a knee that is suddenly hot and swollen, or a calf that hurts after an injection or a long drive. Put the MedlinePlus signs above the booking button, in plain words: call [phone] if you cannot bear weight on your knee, if you have severe pain even at rest, if you have a fever, redness or warmth around the knee or marked swelling, or if you have pain, swelling, numbness, tingling or bluish color in the calf below the sore knee. The MedlinePlus encyclopedia article Deep vein thrombosis (review date April 1, 2025) tells a person with a clot in the leg to go to the emergency room or call 911 if they develop chest pain, cough up blood, have difficulty breathing, faint or lose consciousness. Add that 911 line, and ask the clinicians to review both lines before they go live.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools. A tool should hand any message about chest pain or trouble breathing to the 911 line and alert staff, pass a hot swollen knee or a painful calf to the on-call clinician, and never offer the next open slot to a person who describes those signs. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Phrases that need rewriting:

• “Swollen knee after your injection? Book a follow-up online.” Put the clinic’s number and the warning signs first, and the booking form after it.
• “Text us a photo of your knee and we’ll tell you if it’s normal.” A text line is not watched in real time. Say who reads messages and when, and give 911 for emergencies.

Injections, braces and devices: describe the FDA status

Injection offers are the center of knee clinic advertising, and the products behind them are regulated in different ways: as drugs, as biologics or as devices, each with its own labelled use. Describe each product only in the terms of its own FDA status and labelled use, name no product in ads, and let the clinician explain the choices, risks and costs at the visit. NIAMS says a doctor decides the number of injections a person should receive and their timing, so a package of a set number of shots sold before an exam puts the sale ahead of that decision.

For devices, such as braces, home therapy units or the systems used to prepare an injection, the FDA page Premarket Notification 510(k) (content current as of August 22, 2024) says FDA’s order finding a device substantially equivalent “clears” it for commercial distribution, and under 21 CFR 807.97, any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. A system cleared to prepare a blood sample is not cleared to treat osteoarthritis, and an ad should not suggest it is. Our guides to medical device marketing claims and prosthetics and orthotics marketing cover intended use and bracing.

Joint supplements raise the same problem. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement rebuilds cartilage or treats arthritis, and follow our guide to selling supplements in a medical practice.

Stem cell, exosome and “regenerative” knee offers

Search suggestions for “regrow knee cartilage with stem cells” lead to clinics that sell cell and tissue products for knee pain, and knee clinics receive these offers from product sellers. The FDA page Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024, older than two years) says regenerative medicine therapies have not been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain. It says FDA has received reports of blindness, tumor formation and infections from unapproved products, that a person charged for these products or offered them outside of a clinical trial is likely being deceived and offered a product illegally, and that listing on clinicaltrials.gov or registration with FDA does not mean a product is legally marketed.

Because that page is older than two years, we checked the FDA approved list on October 30, 2026, as described above: the only knee product on it is labelled for full-thickness cartilage defects, not osteoarthritis. A knee clinic should not offer, advertise or refer for cell, fat-derived, cord blood, amniotic or exosome products for osteoarthritis outside an FDA-overseen trial. If the clinic takes part in a trial, recruitment follows our guide to clinical trial recruitment ads, and the ad describes a study, not a treatment.

Phrases that need rewriting:

• “Regenerative knee therapy using your body’s own healing cells.” FDA says regenerative medicine therapies are not approved for any orthopedic condition such as osteoarthritis. Remove it.
• “Registered with FDA and listed on clinicaltrials.gov.” FDA says neither means a product is legally marketed. Remove it.
• “FDA approved cartilage repair, now for arthritis.” The approved knee product is labelled for cartilage defects, not osteoarthritis. Remove it.

Free seminar meals, free screenings and prices

Knee pain seminars with a free lunch at a restaurant, followed by free knee screenings, are a familiar channel for knee clinics that sell injection packages. Two sets of rules apply. A “free” meal or screening follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. And under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. A meal, a gift card or a free service offered to people over 65 to bring them into a clinic needs counsel’s review before it runs.

A screening is not a diagnosis, and the event page should say a provider diagnoses osteoarthritis from symptoms, an exam and imaging. Our guides to patient education seminars and health fair screening events cover the event side, and our guides to advertising cash prices and good faith estimates for self-pay patients cover injection packages paid out of pocket. State what a package includes, what it costs, and the refund terms if a clinician decides after the exam that the package is not the right fit.

Coverage claims need the same care. The Medicare.gov page Physical therapy services, checked on October 30, 2026, says Part B helps pay for medically necessary outpatient physical therapy if the person is eligible, and that after the Part B deductible the person pays 20 percent of the Medicare-approved amount. Quote coverage in those terms for the services Medicare.gov describes, and say the clinic checks coverage for each patient’s plan rather than saying a treatment “is covered by Medicare”. Our guide to marketing to Medicare patients covers the wider rules.

Referrals, product makers and suppliers

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a knee clinic, keep these points:

• Do not accept free staff, free seminar funding or marketing help from an injection product maker, a brace supplier or a lab tied to orders, without counsel’s review; our guide to Open Payments covers reported payments from manufacturers.
• Give patients a choice of brace and equipment suppliers, and do not steer orders to one supplier in exchange for anything of value; our guide to DME supplier marketing covers the supplier side.
• Referral programs with primary care, chiropractors, physical therapists and surgeons follow our guide to patient and physician referrals.
• Do not pay per lead or per booked patient to a marketing company that recruits Medicare patients for injection packages.

Privacy, pixels and ads

A visit to a knee arthritis page, a quiz about knee pain or a request for an injection consult says something about a person’s health. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a list of patients with arthritis.

Under 45 CFR 164.501, a reminder about the practice’s own treatment for an individual, such as a follow-up visit, can fall outside the definition of marketing, while a message that promotes a third party’s product, such as a brace maker’s product or a supplement, generally needs a signed authorization under 45 CFR 164.508. Reminder texts name no condition, no result and no product in the message text.

Patient stories

A story from a patient who walks farther after treatment is the strongest pull a knee clinic has, and the hardest to use fairly for a condition that varies from person to person. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. A story should not say the patient avoided surgery for good or got new cartilage, and should add a plain line that osteoarthritis cannot be cured and results differ.

Get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, and consent for any photo or video. Name no injection, device or supplement, say if the patient received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two knee clinic pages

Illustration: a page reads “Bone on bone? Regrow your cartilage and avoid knee replacement forever with our regenerative gel and stem cell program, registered with FDA. Join us for a free steak lunch and free knee screening, and ask about our 6-shot package. Works for 9 out of 10 patients.” It promises a reversal the sources say is not possible, offers a cell product FDA says is not approved for any orthopedic condition, misreads FDA registration, offers a meal to bring in Medicare patients, sells a set number of shots before an exam, and uses an outcome number with no source.

Illustration: a second page for the same practice reads “At [Practice name], [Clinician name, license] leads our knee arthritis clinic. Osteoarthritis cannot be cured, but symptoms can be controlled. Your plan may include exercise and physical therapy, weight management, a fitted brace, medicines or injections, and when other treatments are not helping, a referral to a surgeon. We explain each option, its risks and its cost at your visit. Call [phone] if you cannot bear weight on your knee, have a fever or a hot, swollen knee, or have pain or swelling in your calf. Call 911 for chest pain or trouble breathing. Call [phone] during [days and hours] to book.” It quotes what the sources say, puts the warning signs first, and promises nothing it cannot show.

Checklist before a knee clinic campaign goes live

• NIAMS and MedlinePlus pages named and dated, with pages older than two years marked and checked against newer FDA label data and the FDA cell and gene therapy list at each review.
• The MedlinePlus warning signs and the clinic’s number above any booking button, plus the 911 line for chest pain or trouble breathing, in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools.
• No cure, reversal, “regrow cartilage” or “avoid surgery forever” claims; treatment goals described in the NIAMS terms, with surgery named as an option.
• Injections, braces and devices described only in the terms of their FDA status and labelled use; “cleared” never written as “approved”; no product names in ads.
• No stem cell, exosome or other regenerative offers for osteoarthritis outside an FDA-overseen trial; no “registered with FDA” wording as a selling point.
• No package of a set number of injections sold before an exam; prices, what is included and refund terms stated.
• Free meals, gifts and screenings reviewed by counsel under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5) before they run.
• Coverage quoted from Medicare.gov and checked per patient.
• No free staff, seminar funding or marketing help from product makers or suppliers tied to orders without counsel’s review; patients choose their supplier.
• Form answers and bookings stay out of pixels and ad audiences; targeting by place and search terms only.
• Stories have signed authorizations, make no results claim, and say osteoarthritis cannot be cured and results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including orthopedic, sports medicine, pain, primary care and physical therapy practices that run knee clinics. For a knee clinic, that means a site that quotes NIAMS and MedlinePlus as written and dated, puts the warning signs and the clinic’s number above the booking button, answers “can knee arthritis be reversed” searches without a promise, and keeps stem cell offers, seminar meals and supplier ties off the page, plus referral and appointment request pages that keep answers off the web and away from tracking tools. Our front desk tools hand chest pain and breathing complaints to the 911 line and other warning signs to the on-call number, and do not triage symptoms. We do not decide who needs treatment; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NIAMS: Osteoarthritis (last reviewed September 2023)
• NIAMS: Osteoarthritis: Diagnosis, Treatment, and Steps to Take (last reviewed September 2023)
• MedlinePlus: Osteoarthritis (last updated January 8, 2024)
• MedlinePlus encyclopedia: Osteoarthritis (review date April 9, 2026)
• MedlinePlus encyclopedia: Knee pain (review date November 7, 2024)
• MedlinePlus encyclopedia: Deep vein thrombosis (review date April 1, 2025)
• openFDA: Drug labeling API (searched October 30, 2026)
• FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024)
• FDA: Approved Cellular and Gene Therapy Products (content current as of September 17, 2026)
• FDA: product page for the approved knee cartilage defect product (content current as of August 26, 2024)
• Medicare.gov: Physical therapy services (checked October 30, 2026)
• FDA: Premarket Notification 510(k) (content current as of August 22, 2024)
• 21 CFR 807.97: Misbranding by reference to premarket notification
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing